Corvus Pharmaceuticals (CRVS) Liabilities and Shareholders Equity (2015 - 2026)

Corvus Pharmaceuticals' Liabilities and Shareholders Equity history runs 12 years deep, the most recent figure standing at $253.2 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 325.98% year-over-year to $253.2 million; the TTM figure through Mar 2026 stood at $494.2 million (up 96.35% YoY), while the FY2025 annual figure was $71.1 million, up 3.21% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $253.2 million, up from $71.1 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $253.2 million in Q1 2026, with the low at $40.1 million in Q1 2024.
• The 5-year median for Liabilities and Shareholders Equity is $68.2 million (2022), against an average of $79.0 million.
• The sharpest annual moves came in 2023 and 2026: Liabilities and Shareholders Equity slumped 42.54% in 2023, then soared 325.98% in 2026.
• Corvus Pharmaceuticals' Liabilities and Shareholders Equity stood at $68.2 million in 2022, then tumbled by 33.25% to $45.6 million in 2023, then jumped by 51.27% to $68.9 million in 2024, then climbed by 3.21% to $71.1 million in 2025, then soared by 256.02% to $253.2 million in 2026.
• Business Quant data shows CRVS's Liabilities and Shareholders Equity at $253.2 million in Q1 2026, $71.1 million in Q4 2025, and $80.5 million in Q3 2025.